Mitchell Center for Alzheimer's Disease and Related Brain Disorders, Department of Neurology, University of Texas Medical School at Houston, Texas, United States of America.
Universidad de los Andes, Facultad de Medicina, 2200 San Carlos de Apoquindo Av., Las Condes, Santiago 7620001, Chile.
Sci Rep. 2016 Aug 30;6:32338. doi: 10.1038/srep32338.
Natural forms of prion diseases frequently originate by oral (p.o.) infection. However, quantitative information on the gastro-intestinal (GI) absorption of prions (i.e. the bioavailability and subsequent biodistribution) is mostly unknown. The main goal of this study was to evaluate the fate of prions after oral administration, using highly purified radiolabeled PrP(Sc). The results showed a bi-phasic reduction of PrP(Sc) with time in the GI, except for the ileum and colon which showed sustained increases peaking at 3-6 hr, respectively. Plasma and whole blood (125)I-PrP(Sc) reached maximal levels by 30 min and 3 hr, respectively, and blood levels were constantly higher than plasma. Upon crossing the GI-tract (125)I-PrP(Sc) became associated to blood cells, suggesting that binding to cells decreased the biological clearance of the agent. Size-exclusion chromatography revealed that oligomeric (125)I-PrP(Sc) were transported from the intestinal tract, and protein misfolding cyclic amplification showed that PrP(Sc) in organs and blood retained the typical prion self-replicating ability. Pharmacokinetic analysis found the oral bioavailability of (125)I-PrP(Sc) to be 33.6%. Interestingly, (125)I-PrP(Sc) reached the brain in a quantity equivalent to the minimum amount needed to initiate prion disease. Our findings provide a comprehensive and quantitative study of the fate of prions upon oral infection.
天然形式的朊病毒病通常通过口服(p.o.)感染起源。然而,关于朊病毒(即生物利用度和随后的生物分布)的胃肠道(GI)吸收的定量信息大多未知。本研究的主要目的是使用高度纯化的放射性标记 PrP(Sc) 来评估口服后朊病毒的命运。结果表明,除回肠和结肠外,在 GI 中,PrP(Sc) 随时间呈双相减少,回肠和结肠分别在 3-6 小时达到持续增加的峰值。血浆和全血(125)I-PrP(Sc)在 30 分钟和 3 小时时分别达到最大水平,且血液水平始终高于血浆。穿过胃肠道后(125)I-PrP(Sc)与血细胞结合,表明与细胞结合降低了该物质的生物清除率。排阻色谱表明,寡聚(125)I-PrP(Sc)从肠道转运,蛋白质错误折叠循环扩增表明,器官和血液中的 PrP(Sc)保留了典型的朊病毒自我复制能力。药代动力学分析发现(125)I-PrP(Sc)的口服生物利用度为 33.6%。有趣的是,(125)I-PrP(Sc)到达大脑的量相当于引发朊病毒病所需的最小量。我们的研究结果提供了关于口服感染后朊病毒命运的全面和定量研究。